Standard BioTools Inc. (LAB)
Nasdaq · Healthcare · Medical Devices
$0.763+2.46%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $300M
- 52-week range
- $0.63 – $1.72
- 52-week change
- −43.94%
- EPS (trailing)
- −$0.13
- Next earnings
- Nov 3, 2026
Fiscal year to Dec 2025
- Revenue
- $85.3M (−6.24%)
- Net income
- −$74.9M
- Operating margin
- −129.2%
- Diluted EPS
- −$0.20
- Free cash flow
- −$82.7M
From the company’s annual report on SEC EDGAR.
About Standard BioTools Inc.
Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consumables, and assays for clinical and diagnostic uses. The company also provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications.
Headquarters: Boston, United States · 385 employees · standardbio.com